# US 2012/0252864 A1 · Substituted isoindoline-1,3-dione derivatives

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0252864 A1
- Document ID: US20120252864A1
- Status: Published application
- Kind: A1
- Application number: 13/364,724
- Filed: 2012-02-02
- Published: 2012-10-04
- Earliest claimed: 2009-06-18
- Assignees: Concert Pharmaceuticals, Inc.
- Inventors: Julie F. Liu
- Web page: https://patentgrep.com/patent/US20120252864A1

## CPC

- C07D 209/48: with oxygen atoms in positions 1 and 3, e.g. phthalimide
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/02: Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/04: Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 11/06: Antiasthmatics
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/04: Antipruritics
- A61P 17/06: Antipsoriatics
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 19/04: for non-specific disorders of the connective tissue
- A61P 19/08: for bone diseases, e.g. rachitism, Paget's disease
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 27/02: Ophthalmic agents
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/04: Antibacterial agents
- A61P 31/08: for leprosy
- A61P 31/14: for RNA viruses
- A61P 31/18: for HIV
- A61P 33/06: Antimalarials
- A61P 35/00: Antineoplastic agents
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/02: Immunomodulators
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 39/00: General protective or antinoxious agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07B 59/002: {Heterocyclic compounds}
- C07D 207/404: with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. succinimide
- C07D 209/46: with an oxygen atom in position 1
- C07D 405/12: linked by a chain containing hetero atoms as chain links
- C07B 2200/05: Isotopically modified compounds, e.g. labelled
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

This invention relates to novel substituted isoindoline-1,3-dione derivatives and pharmaceutically acceptable salts thereof. More specifically, the invention relates to novel substituted isoindoline-1,3-dione derivatives that are analogues of apremilast. This invention also provides compositions comprising a compound of this invention and a carrier and the use of disclosed compounds and compositions in methods of treating diseases and conditions that are beneficially treated by administering apremilast.

## Claims

### Claim at position 1

1-19. (canceled)

### Claim 20

A method of inhibiting PDE4 in a subject in need thereof, comprising administering to the subject an effective amount of a compound of Formula I:
or a pharmaceutically acceptable salt thereof, wherein:
R1 is selected from CH3, CH2D, CHD2, and CD3
R2 is methyl or CD3;
R3 is CD3;
R4 is an ethyl group substituted with zero to five deuterium, or is a cyclopentyl group substituted with zero to nine deuterium;
X is C═O;
each of Y1a, Y1b, Y2, Y3, Y4, Y5, Y7 and Y8 is independently selected from H and D; and
Y6 is selected from Cl, H, and D.

### Claim 21

A method of reducing TNF-α levels in a subject in need thereof, comprising administering to the subject an effective amount of a compound Formula I:
or a pharmaceutically acceptable salt thereof, wherein:
R1 is selected from CH3, CH2D, CHD2, and CD3;
R2 is methyl or CD3;
R3 is CD3;
R4 is an ethyl group substituted with zero to five deuterium, or is a cyclopentyl group substituted with zero to nine deuterium;
X is C═O;
each of Y1a, Y1b, Y2, Y3, Y4, Y5, Y7, and Y8 is independently selected from H and D; and
Y6 is selected from Cl, H, and D.

### Claim 22

A method of treating a disease selected from the group consisting of septic shock, sepsis, endotoxic shock, hemodynamic shock and sepsis syndrome, post ischemic reperfusion injury, malaria, mycobacterial infection, meningitis, psoriasis, sarcoidosis, psoriatic arthritis, Behçet's Disease, prurigo nodularis, lupus, uveitis, congestive heart failure, fibrotic disease, cachexia, graft rejection, cancer, autoimmune disease, opportunistic infections in AIDS, rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis, other arthritic conditions, Crohn's disease, ulcerative colitis, multiple sclerosis, systemic lupus erythrematosis, ENL in leprosy, radiation damage, hyperoxic alveolar injury, undesirable angiogenesis, inflammatory disease, arthritis, inflammatory bowel disease, aphthous ulcers, asthma, adult respiratory distress syndrome, and AIDS, in a patient in need thereof comprising administering to the patient an effective amount of a compound of Formula I:
or a pharmaceutically acceptable salt thereof, wherein:
R1 is selected from CH3, CH2D, CHD2, and CD3;
R2 is methyl or CD3;
R3 is CD3;
R4 is an ethyl group substituted with zero to five deuterium, or is a cyclopentyl group substituted with zero to nine deuterium;
X is C═O;
each of Y1a, Y1b, Y2, Y3, Y4, Y5, Y7 and Y8 is independently selected from H and D; and
Y6 is selected from Cl, H, and D.

### Claim 23 (depends on 22)

The method of claim 22, wherein the condition is psoriasis or sarcoidosis.

### Claim 24 (depends on 23)

The method of claim 23, wherein psoriasis is plaque-type psoriasis or refractory psoriasis.

### Claim 25 (depends on 23)

The method of claim 23, wherein sarcoidosis is cutaneous sarcoidosis.

### Claim 26 (depends on 22)

The method of claim 22, wherein lupus is cutaneous lupus.

### Claim 27 (depends on 22)

The method of claim 22, wherein the disease is selected from Behçet's Disease, autoimmune disease, and rheumatoid arthritis.

### Claim 28 (depends on 22)

The method of claim 22, wherein the compound of Formula I has predominantly the (S) configuration at the carbon attached to Y2 and is represented by the following Formula Ia:

### Claim 29 (depends on 22)

The method of claim 22, wherein Y6, Y7 and Y8 are the same.

### Claim 30 (depends on 22)

The method of claim 22, wherein Y1a and Y1b are the same.

### Claim 31 (depends on 22)

The method of claim 22, wherein Y3, Y4 and Y5 are the same.

### Claim 32 (depends on 22)

The method of claim 22, wherein R1 is CH3 or CD3.

### Claim 33 (depends on 22)

The method of claim 22, wherein R4 is CD2CD3.

### Claim 34 (depends on 28)

The method of claim 28, wherein Y6, Y7 and Y8 are the same.

### Claim 35 (depends on 28)

The method of claim 28, wherein Y1a and Y1b are the same.

### Claim 36 (depends on 28)

The method of claim 28, wherein Y3, Y4 and Y5 are the same.

### Claim 37 (depends on 28)

The method of claim 28, wherein R1 is CH3 or CD3.

### Claim 38 (depends on 28)

The method of claim 28, wherein R4 is CD2CD3.

### Claim 39 (depends on 22)

The method of claim 22, wherein the compound is selected from the group consisting of
or a pharmaceutically acceptable salt of any of the foregoing.

### Claim 40 (depends on 28)

The method of claim 28, wherein the compound is selected from the group consisting of
or a pharmaceutically acceptable salt of any of the foregoing.

### Claim 41 (depends on 22)

The method of claim 22 wherein any atom not designated as deuterium is present at its natural isotopic abundance.
